Thank you. And, I mean, it's really important, what you talked about, this synergistic action with Lenvatinib as well. And that becomes even more important that Fostrox is selective in the liver because otherwise, you might also enhance the toxicity in the liver. And as Fredrik already said, we have a patient population with poor liver function. Tumor selectivity is paramount when treating liver tumors. So, we don't want to impair liver function further. So, to confirm the results from the biopsy that Fredrik just talked about, we could see that what you see here on the slide is longitudinal liver enzyme data, ALT, and AST. It's to the left. And also supporting the fact that we didn't have any sort of negative effect in combination with platinum. Something else that you often look at when examining liver cancer patients is the ALBI score. And that is assessed to evaluate liver function. It's albumin plus bilirubin. This analysis that we have from our data shows that the ALBI score, as you can see to the right here, was stable with no change in the score. And that further supports the selectivity and also the tolerability, which is a prerequisite for efficacy. And in order to stay on the treatment to have a longer-term benefit, I think we should move to the next slide. In our earlier presentation, we showcased encouraging efficacy data. I'm sure that you have seen this already, with an overall response rate of 24% and a disease control rate of 81% in this population.
Again, it is a poor prognosis. Population. And at ESMO GI, the estimated median time to progression was 10.8 months, which is very long in this patient population.
At that time, five patients were still remaining on this trial. At this point in the study, the data has matured enough to allow us to use the standard Kaplan-Meier approach with the median time to progression (TTP). And this is an estimate of what the median time to progression is most likely to be at the time of the final read of the study. So this is what we normally use. We have presented before, like an actual time point, which is not the standard way of doing it, but that has been due to the fact that the data has not been mature enough. We can go to the next slide. So, to put this median time to progression (TTP) of 10.8 months, seen in this phase 1B2A study into context, we are comparing it with Lenvima and other second-line treatments in HCC. And when we do that, it becomes clear that 10.8 months is quite a bit longer than the around four months in median TTP or PFS seen in studies that we have listed here to the right.
This is not a comprehensive list, but as you remember, we have talked about before, this is like a stone or a data desert where we don't have much data. So with the Lenvima data in second-line after immunotherapy, it's mainly retrospective data and what we can see that this is the first part of the list is that we have TTP or PFS around 2 to 6 months, and this is really similar to what is seen with other TKIs in the second-line HCC. And at the bottom of this list, uh, this is the data that was recently presented at ESMO. And it showed a disappointing PFS of only 2.8 months. What was used here was an immunotherapy combination in this case, pembrolizumab and regorafenib, in the second line after using an immunotherapy combination in the first line setting.
And this really supports the need for switching to another mechanism of action than what was actually used in the first line study. So next slide. So, Jens has already talked a little bit about this, but we are excited. We are going to present data again. And the impact of the data from Medivir was discussed with Dr. Sean at ESMO. And that interview is available on the Medivir website. I have not looked at it yet, it is available on the Medivir website.
ESMO GI in Barcelona is really around the corner, and we will present data on the 16th of September from this phase 1B2A study with Fostrox. And then we will present mature safety data because the primary endpoint was safety. And again, this is a prerequisite for efficacy. And we also now have mature efficacy results. Uh, this data will then later during the same day be shared and discussed in a webcast with Dr. Sean and myself.
And, we will provide more information shortly. We can go to the next slide. So what is the next step here? Based on the encouraging data that you have seen from the phase 1B2A, we are continuing the planning and preparation for the randomized phase 2B study with Fostrox in combination with Lenvima versus Lenvima alone. And this is in second-line advanced HCC that have all received prior immunotherapy combination in the first line. The first part of this study, as you can see here on the slide, will be a dose optimization run-in. And the second part will continue with the selected dose.
Also, randomization as you can see here. And the recruitment in this trial will take place in Europe, Asia, and in the US. And with our selection here. The feasibility study is currently ongoing. And with that, I will leave it to you.